1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,170 | 0,173 | 08:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | VIVA BIOTECH (01873): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| Do | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Do | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Do | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| Do | VIVA BIOTECH (01873): 2024 ANNUAL REPORT | - | HKEx | ||
| 07.04. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 301 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 98 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen | |
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 27.03. | VIVA BIOTECH (01873): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON THE PASSING OF U.S. FDA ON-SITE INSPECTION BY LANGHUA PHARMACEUTICAL, A WHOLLY-OWNED SUBSIDIARY | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 3 | HKEx | ||
| 17.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.03. | VIVA BIOTECH (01873): POSITIVE PROFIT ALERT | 2 | HKEx | ||
| 16.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 06.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 23.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 11.12.24 | Viva Biotech Establishes New Branch in Boston | 3 | Contract Pharma | ||
| 11.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,156 | +0,45 % | Valneva-Aktie: Unfassbare Prognose! | News von Trading-Treff.de Valneva hinterlässt am Osterwochenende einige Fragezeichen. An sich hat sich die Aktie wieder schön erholt. Sie legte insgesam 1,1 % zu. Die Notierungen sind auf 3,04 Euro... ► Artikel lesen | |
| NOVONESIS | 56,12 | +0,21 % | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | ||
| GENMAB | 181,05 | +0,44 % | GENMAB A/S - 6-K, Report of foreign issuer | ||
| ARBUTUS BIOPHARMA | 2,840 | -3,07 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| BEIGENE LTD ADR | 224,00 | -0,88 % | BEIGENE (06160): OVERSEAS REGULATORY ANNOUNCEMENT - FORM F-6 | ||
| MOLECULIN BIOTECH | 0,735 | -100,00 % | Moleculin Biotech, Inc. - 10-K/A, Annual Report | ||
| VERICEL | 36,000 | -0,55 % | Vericel Corporation: Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 | ||
| SINO BIOPHARM | 0,428 | -2,68 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF PENPULIMAB INJECTION BY THE US FDA | ||
| SENSEI BIOTHERAPEUTICS | 0,327 | -0,91 % | Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress | - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate... ► Artikel lesen | |
| ZAI LAB LTD ADR | 29,400 | -1,34 % | ZAI LAB (09688): NOTICE OF AUDIT COMMITTEE ACTION AND DATE OF PUBLICATION OF FIRST QUARTER 2025 RESULTS ANNOUNCEMENT | ||
| BIOXCEL THERAPEUTICS | 1,365 | -100,00 % | BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia | Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash following closing of recent equity financing... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,704 | 0,00 % | MustGrow Biologics Corp.: MustGrow Adds New Biostimulants and Inoculants to Canadian Product Portfolio | Saskatoon, Saskatchewan--(Newsfile Corp. - April 1, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
| REGENXBIO | 7,700 | -4,94 % | Regenxbio Aktie: Überschaubare Aussichten | Regenxbio verzeichnet aktuell einen Kursrückgang von 3,45 Prozent auf 7,00 Euro, wobei die Aktie in den letzten sieben Tagen sogar über 13 Prozent an Wert eingebüßt hat. Das Unternehmen hat kürzlich... ► Artikel lesen | |
| AKEBIA | 1,909 | -4,45 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa | CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,330 | -1,79 % | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress | Financial Performance: Strong Year-over-Year Improvement- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.- ... ► Artikel lesen |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,166 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.
